Houston, TX, (March 31, 2005) Cytogenix, Inc. (CYGX: OTC: BB)
CytoGenix, Inc. (CYGX: OTC: BB) announces the preclinical development of CY403 a antibacterial compound that is specific against all strains of Staphylococcus aureus, especially resistant strains such as MRSA - Methicillin-resistant and VRSA - Vancomycin- resistant, popularly referred to as "superbugs".
The incidence of infection by resistant bacteria is increasing rapidly and is most common in at-risk hospital patients. In a report titled "Proportion of S. aureus Nosocomial Infections Resistant to Oxacillin (MRSA) Among Intensive Care Unit Patients, 1989-2003", the U.S. Centers for Disease Control and Prevention - CDC shows that the proportion of ICU patients with resistant staph infections has grown from 30% in 1989 to 60% in 2003.
Dr. Yin Chen, CytoGenix' Vice President and Chief Scientific Officer commented, "The introduction of CY403 into the preclinical product development phase within three months after target discovery and validation demonstrates the true value of our gene silencing technology. We have the capability to move very efficiently from discovery to product candidate in a matter of a few months."
"Recent laboratory studies show that this compound rapidly kills MRSA and prevents further growth. Evidence shows that this compound is a powerful bacteriacidal as well as a bacteriastatic agent against MRSA. Further studies will confirm these capabilities in animal and human trials." added Dr. Chen.
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 48 international or US pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: CytoGenix, Inc., Communications Director - Juan Ferreira, (407) 774-9949
